FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3193746989> ?p ?o ?g. }

• W3193746989 endingPage "105806" @default.
• W3193746989 startingPage "105806" @default.
• W3193746989 abstract "RAS proteins (HRAS, KRAS, NRAS) participate in many physiological signal transduction processes related to cell growth, division, and survival. The RAS proteins are small (188/189 amino acid residues) and they function as GTPases. These proteins toggle between inactive and functional forms; the conversion of inactive RAS-GDP to active RAS-GTP as mediated by guanine nucleotide exchange factors (GEFs) turns the switch on and the intrinsic RAS-GTPase activity stimulated by the GTPase activating proteins (GAPs) turns the switch off. RAS is upstream to the RAS-RAF-MEK-ERK and the PI3-kinase-AKT signaling modules. Importantly, the overall incidence of RAS mutations in all cancers is about 19% and RAS mutants have been a pharmacological target for more than three decades. About 84% of all RAS mutations involve KRAS. Except for the GTP/GDP binding site, the RAS proteins lack other deep surface pockets thereby hindering efforts to identify high-affinity antagonists; thus, they have been considered to be undruggable. KRAS mutations frequently occur in lung, colorectal, and pancreatic cancers, the three most deadly cancers in the United States. Studies within the last decade demonstrated that the covalent modification of KRAS C12, which accounts for about 10% of all RAS mutations, led to the discovery of an adjacent pocket (called the switch II pocket) that accommodated a portion of the drug. This led to the development of sotorasib as a second-line treatment of KRASG12C-mutant non-small cell lung cancer. Considerable effort also has been expended to develop MAP kinase and PI3-kinase pathway inhibitors as indirect RAS antagonists." @default.
• W3193746989 created "2021-08-30" @default.
• W3193746989 creator A5050801402 @default.
• W3193746989 date "2021-10-01" @default.
• W3193746989 modified "2023-10-16" @default.
• W3193746989 title "Blockade of mutant RAS oncogenic signaling with a special emphasis on KRAS" @default.
• W3193746989 cites W1254214770 @default.
• W3193746989 cites W1881469793 @default.
• W3193746989 cites W1977267072 @default.
• W3193746989 cites W1978392336 @default.
• W3193746989 cites W1978572651 @default.
• W3193746989 cites W1983759759 @default.
• W3193746989 cites W1992477322 @default.
• W3193746989 cites W1997385847 @default.
• W3193746989 cites W1998132110 @default.
• W3193746989 cites W1999275756 @default.
• W3193746989 cites W2002252224 @default.
• W3193746989 cites W2010993054 @default.
• W3193746989 cites W2011857798 @default.
• W3193746989 cites W2017499074 @default.
• W3193746989 cites W2021031498 @default.
• W3193746989 cites W2022495797 @default.
• W3193746989 cites W2022920832 @default.
• W3193746989 cites W2028519621 @default.
• W3193746989 cites W2034975420 @default.
• W3193746989 cites W2055380229 @default.
• W3193746989 cites W2057159445 @default.
• W3193746989 cites W2065004493 @default.
• W3193746989 cites W2067900929 @default.
• W3193746989 cites W2070727232 @default.
• W3193746989 cites W2073473480 @default.
• W3193746989 cites W2082777785 @default.
• W3193746989 cites W2082839106 @default.
• W3193746989 cites W2083690533 @default.
• W3193746989 cites W2083695927 @default.
• W3193746989 cites W2091661023 @default.
• W3193746989 cites W2093691792 @default.
• W3193746989 cites W2094068658 @default.
• W3193746989 cites W2101653483 @default.
• W3193746989 cites W2114752093 @default.
• W3193746989 cites W2118549562 @default.
• W3193746989 cites W2128339707 @default.
• W3193746989 cites W2131376017 @default.
• W3193746989 cites W2135732933 @default.
• W3193746989 cites W2142454421 @default.
• W3193746989 cites W2160586729 @default.
• W3193746989 cites W2164682544 @default.
• W3193746989 cites W2500954855 @default.
• W3193746989 cites W2517550655 @default.
• W3193746989 cites W2519119260 @default.
• W3193746989 cites W2560660889 @default.
• W3193746989 cites W2567682222 @default.
• W3193746989 cites W2586891229 @default.
• W3193746989 cites W2613467753 @default.
• W3193746989 cites W2616761213 @default.
• W3193746989 cites W2728981453 @default.
• W3193746989 cites W2732767128 @default.
• W3193746989 cites W2774483419 @default.
• W3193746989 cites W2777554180 @default.
• W3193746989 cites W2778033843 @default.
• W3193746989 cites W2789281724 @default.
• W3193746989 cites W2794353845 @default.
• W3193746989 cites W2796153225 @default.
• W3193746989 cites W2802805088 @default.
• W3193746989 cites W2886399358 @default.
• W3193746989 cites W2887317445 @default.
• W3193746989 cites W2896658886 @default.
• W3193746989 cites W2897815318 @default.
• W3193746989 cites W2901442091 @default.
• W3193746989 cites W2903084459 @default.
• W3193746989 cites W2904506792 @default.
• W3193746989 cites W2913208997 @default.
• W3193746989 cites W2916967884 @default.
• W3193746989 cites W2922159934 @default.
• W3193746989 cites W2964857152 @default.
• W3193746989 cites W2968495081 @default.
• W3193746989 cites W2980433900 @default.
• W3193746989 cites W2984955289 @default.
• W3193746989 cites W2985910195 @default.
• W3193746989 cites W2995463243 @default.
• W3193746989 cites W2998581726 @default.
• W3193746989 cites W3011687118 @default.
• W3193746989 cites W3013377779 @default.
• W3193746989 cites W3014882016 @default.
• W3193746989 cites W3034504519 @default.
• W3193746989 cites W3042326408 @default.
• W3193746989 cites W3087229737 @default.
• W3193746989 cites W3089334610 @default.
• W3193746989 cites W3092229078 @default.
• W3193746989 cites W3097863157 @default.
• W3193746989 cites W3107443911 @default.
• W3193746989 cites W3119005666 @default.
• W3193746989 cites W3120861427 @default.
• W3193746989 cites W3123446037 @default.
• W3193746989 cites W3145046568 @default.
• W3193746989 cites W3150192782 @default.
• W3193746989 cites W3157034076 @default.
• W3193746989 cites W3158279877 @default.

• next